Autoimmune Disease Diagnostics Market to Grow 6.70% CAGR during the Forecast Period 2022 to 2030

Pune, India, November 2022/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Autoimmune Disease Diagnostics Market.

Autoimmune Disease Diagnostics Market - Highlights

Autoimmune disease is a disorder where body’s own immune system starts attacking the healthy cells instead of foreign particles and disease-causing agents. The rising awareness about autoimmune disorders, technological advancement in the healthcare sector and rise in number of cases of autoimmune diseases are the factors driving the growth of the global autoimmune disease diagnostics market. Moreover, strategic collaborations and aggressive strategies by major players are also contributing to the growth of the market. For instance, in May 2018, Myriad Genetics, Inc. has acquired Counsyl, Inc. for USD 375 million, Counsyl is a global leader in genetic testing and personalized medicine segment.

The rising cases of false positive result of autoimmune disorders, scarcity of technicians, and price war between companies are likely to hinder market growth during the forecast period.

Regional Analysis:

The Americas are likely to dominate the global autoimmune disease diagnostics market due to the well-established healthcare sector, adoption of advance technology, and rising prevalence of autoimmune disorders. The European market is expected to be the second-largest autoimmune disease diagnostics market. The growing healthcare industry, presence of major market players in the region, and increasing automation in laboratories are the factors responsible for growth of the autoimmune disease diagnostics market in the region. Asia-Pacific is anticipated to be the fastest-growing autoimmune disease diagnostics market during the forecast period owing to the increase in population, rising prevalence of autoimmune disorders, and initiatives by government and private organizations for development of healthcare sector. The market in the Middle East & Africa is likely to account for the smallest share of the global autoimmune disease diagnostics market.

Segmentation:

The global autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.

The market, by disease type, has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further classified into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been divided into inflammatory bowel disease, thyroid, type 1 diabetes, and others.

On the basis of test type, the market has been segregated into  western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.

The end-user segment has been divided into, has been segmented into hospitals, diagnostics centers, research laboratories, and others

Explore In-depth Details: Autoimmune Disease Diagnostics Market Research Report

Key Players:

Some of the key players in the global autoimmune disease diagnostics market are Thermo Fisher Scientific, bioMérieux SA, Beckman Coulter, Inc., Siemens Healthcare Private Limited,Inova Diagnostics, Bio-rad Laboratories, AstraZeneca, EUROIMMUN AG, F. Hoffmann-la Roche,  Inc.,Myriad Genetics, Inc., Hemagen Diagnostics, Inc., and Trinity Biotech Plc.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com .